These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2188399)

  • 1. m-CPP: a tool for studying behavioural responses associated with 5-HT1c receptors.
    Curzon G; Kennett GA
    Trends Pharmacol Sci; 1990 May; 11(5):181-2. PubMed ID: 2188399
    [No Abstract]   [Full Text] [Related]  

  • 2. Modulation of the 5-HT1C receptor-mediated behavior by 5-HT2, but not 5-HT1A, receptor activation.
    Chojnacka-Wójcik E
    Pol J Pharmacol Pharm; 1992; 44(5):427-36. PubMed ID: 1363616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.
    Bagdy G; Graf M; Anheuer ZE; Modos EA; Kantor S
    Int J Neuropsychopharmacol; 2001 Dec; 4(4):399-408. PubMed ID: 11806866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety.
    Gatch MB
    Life Sci; 2003 Aug; 73(11):1347-67. PubMed ID: 12850497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats.
    Gong L; Kostrzewa RM
    Pharmacol Biochem Behav; 1992 Mar; 41(3):621-3. PubMed ID: 1584843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors.
    Kennett GA; Curzon G
    Br J Pharmacol; 1988 May; 94(1):137-47. PubMed ID: 3401632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity.
    Lucki I; Ward HR; Frazer A
    J Pharmacol Exp Ther; 1989 Apr; 249(1):155-64. PubMed ID: 2709329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin.
    Freo U; Holloway HW; Greig NH; Soncrant TT
    Psychopharmacology (Berl); 1992; 107(1):30-8. PubMed ID: 1534179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT1A and 5-HT1C/1D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys.
    Pomerantz SM; Hepner BC; Wertz JM
    Eur J Pharmacol; 1993 Oct; 243(3):227-34. PubMed ID: 8276074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central serotoninmimetic action of phenylpiperazines.
    Maj J; Lewandowska A
    Pol J Pharmacol Pharm; 1980; 32(4):495-504. PubMed ID: 7255267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats.
    Aulakh CS; Hill JL; Murphy DL
    J Pharmacol Exp Ther; 1992 Nov; 263(2):588-95. PubMed ID: 1432690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice.
    Berendsen HH; Broekkamp CL
    Br J Pharmacol; 1990 Nov; 101(3):667-73. PubMed ID: 2150180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze.
    Lin D; Parsons LH
    Pharmacol Biochem Behav; 2002 Apr; 71(4):581-7. PubMed ID: 11888549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats.
    Bagdy G; Szemeredi K; Kanyicska B; Murphy DL
    J Pharmacol Exp Ther; 1989 Jul; 250(1):72-8. PubMed ID: 2746512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists.
    Bagdy G; Sved AF; Murphy DL; Szemeredi K
    Eur J Pharmacol; 1992 Jan; 210(3):285-9. PubMed ID: 1535317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans.
    Murphy DL; Lesch KP; Aulakh CS; Pigott TA
    Pharmacol Rev; 1991 Dec; 43(4):527-52. PubMed ID: 1775507
    [No Abstract]   [Full Text] [Related]  

  • 17. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.
    Kennett GA; Whitton P; Shah K; Curzon G
    Eur J Pharmacol; 1989 May; 164(3):445-54. PubMed ID: 2767117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine.
    Rokosz-Pelc A; Antkiewicz-Michaluk L; Vetulani J
    J Pharm Pharmacol; 1980 Mar; 32(3):220-2. PubMed ID: 6103943
    [No Abstract]   [Full Text] [Related]  

  • 19. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.
    Mueller EA; Murphy DL; Sunderland T
    Psychopharmacology (Berl); 1986; 89(3):388-91. PubMed ID: 3014595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic mianserin or eltoprazine treatment in rats: effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels.
    Rocha B; Rigo M; Di Scala G; Sandner G; Hoyer D
    Eur J Pharmacol; 1994 Sep; 262(1-2):125-31. PubMed ID: 7813563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.